HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

A 285222

a bis(trifluoromethyl)pyrazole compound that inhibits NFAT

Also Known As:

A 185 cpd; A-285 cpd; A-285222; A285 cpd; A285222

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - A 285222: 4

Experts

1.	Gomez, Maria F: 4 articles (01/2018 - 11/2012)
2.	Berglund, Lisa M: 3 articles (01/2018 - 11/2012)
3.	Blanco, Fabiana: 2 articles (01/2018 - 01/2014)
4.	Thorlacius, Henrik: 2 articles (08/2014 - 11/2012)
5.	Zetterqvist, Anna V: 2 articles (01/2014 - 11/2012)
6.	Dutius Andersson, Anna-Maria: 1 article (01/2018)
7.	Gurzeler, Erika: 1 article (01/2018)
8.	Heinonen, Suvi E: 1 article (01/2018)
9.	Jönsson-Rylander, Ann-Cathrine: 1 article (01/2018)
10.	Kotova, Olga: 1 article (01/2018)

Related Diseases

1.	Atherosclerotic Plaque (Atheroma) 01/01/2018 - "In vivo treatment with the nuclear factor of activated T-cells blocker A-285222 for 4 weeks reduced atherosclerotic plaque area and degree of stenosis in the brachiocephalic artery of IGF-II/LDLR-/-ApoB100/100 mice, as assessed non-invasively using ultrasound biomicroscopy prior and after treatment, and histologically after termination. "
2.	Atherosclerosis 01/01/2014 - "In vivo treatment with the NFAT blocker A-285222 for 4 weeks completely inhibited the diabetes-induced aggravation of atherosclerosis, having no effect in non-diabetic mice. " 01/01/2014 - "A-285222 completely blocked this diabetes-driven NFAT activation, but had no impact on the other organs or on splenocyte proliferation or cytokine secretion, ruling out systemic immunosuppression as the mechanism behind reduced atherosclerosis. "
3.	Sepsis (Septicemia) 08/01/2014 - "Moreover, administration of A-285222 restored sepsis-induced T-cell dysfunction, as evidenced by markedly decreased apoptosis and restored proliferative capacity of CD4 T cells. " 08/01/2014 - "Treatment with the NFAT inhibitor A-285222 prior to CLP completely prevented sepsis-induced NFAT activation in all these organs. "
4.	Necrosis 11/01/2012 - "A-285222 also reduced taurocholate-induced increases in levels of amylase, myeloperoxidase, and CXCL2; activation of trypsinogen; necrosis of acinar cells; edema; leukocyte infiltration; and hemorrhage in the pancreas. "
5.	Hyperglycemia 01/01/2014 - "STZ-treated mice exhibited hyperglycemia and higher plasma cholesterol and triglycerides, but these were unaffected by A-285222. "

Related Drugs and Biologics

1.	Cytokines
2.	Trypsinogen
3.	Triglycerides (Triacylglycerol)
4.	Taurocholic Acid (Sodium Taurocholate)
5.	Peroxidase (Myeloperoxidase)
6.	Insulin-Like Growth Factor II (Somatomedin A)
7.	Cholesterol
8.	Amylases

Related Therapies and Procedures

1.	Aftercare (After-Treatment)